ABT-414
Pre-clinicalCompletedDevelopment Stage
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis
— → —
About ABT-414
ABT-414 is a pre-clinical stage product being developed by AbbVie for Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis. The current trial status is completed. This product is registered under clinical trial identifier NCT03123952. Target conditions include Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis.
What happened to similar drugs?
1 of 18 similar drugs in Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis were approved
Hype Score Breakdown
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03123952 | Pre-clinical | Completed |
| NCT01741727 | Phase 1 | Completed |
Competing Products
20 competing products in Glioblastoma or Solid Tumors, Epidermal Growth Factor Receptor (EGFR) Diagnosis